Drug Trial Radar · NCT01767311
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
856
Actual
Start
Dec 20, 2012
Primary completion
Dec 10, 2024
Study completion Dec 10, 2024
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Biogen
- First posted
- Jan 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group study using a Bayesian design with response adaptive randomization across placebo or 5 active arms of lecanemab to determine clinical efficacy and to explore the dose response of lecanemab using a composite clinical score (ADCOMS). BAN2401-G000-201 Core study is an 18-month study in which 3 dose levels (2.5, 5, and 10 mg/kg) are given biweekly (once every 2 weeks) to separate groups of participants and 2 dose levels (5 and 10 mg/kg) are given monthly (once every 4 weeks) to separate groups of participants. Participants will be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Frequent interim analyses will be conducted to continually update randomization allocation on the basis of the primary clinical endpoint. Any participant who completes the study treatment (Visit 42 \[Week 79\] of the Core study) or discontinues the Core Study will be eligible to participate in the Extension Phase, provided they meet the Extension Phase inclusion and exclusion criteria. Participants will receive 10 mg/kg biweekly for up to 60 months or until the drug is commercially available in the country, where the subject resides, or until the benefit-to-risk ratio from treatment with lecanemab is no longer considered favorable, whichever comes first. The Follow-up Visit in the Extension Phase will take place 3 months after the last dose of study drug.
Conditions
- Alzheimer's Disease
Interventions
Lecanemab 2.5 mg/kgDrug
2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
Lecanemab 5.0 mg/kgDrug
5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
Lecanemab 10 mg/kgDrug
10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
Lecanemab 5.0 mg/kgDrug
5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
Lecanemab 10 mg/kgDrug
10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
PlaceboDrug
biweekly (once every 2 weeks) administered as i.v. infusion
Lecanemab 10 mg/kgDrug
10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12Time frame: Core Study Phase: at Month 12
- Core Study Phase: Number of Participants With All Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose of the study drug (Week 1) up to 90 days after last dose of study drug (up to 21 months)
- OLE Phase: Number of Participants With All TEAEs and SAEsTime frame: From first dose of the study drug (Week 1) up to 30 days after last dose of study drug (up to 61 months)
Locations
169 sites in 11 countries. Site status is shown where the registry gives one.
Facility #1
Birmingham, Alabama
Facility #1
Phoenix, Arizona
Facility #1
Tucson, Arizona
Facility #1
Carson, California
Facility #1
Lomita, California
Facility #1
Long Beach, California
Facility #1
Los Alamitos, California
Facility #1
Los Angeles, California
Facility #2
Los Angeles, California
Facility #3
Los Angeles, California
Facility #1
Orange, California
Facility #1
Oxnard, California
Facility #1
San Diego, California
Facility #1
Denver, Colorado
Facility #1
New Haven, Connecticut
Facility #2
New Haven, Connecticut
Facility #1
Atlantis, Florida
Facility #1
Boca Raton, Florida
Facility #2
Boca Raton, Florida
Facility #1
Bradenton, Florida
Facility #1
Deerfield Beach, Florida
Facility #1
Delray Beach, Florida
Facility #1
Fort Myers, Florida
Facility #1
Hallandale, Florida
Facility #1
Hialeah, Florida
Facility #1
Lake Worth, Florida
Facility #1
Leesburg, Florida
Facility #2
Leesburg, Florida
Facility #1
Miami, Florida
Facility #2
Miami, Florida
Facility #3
Miami, Florida
Facility #1
Miami Springs, Florida
Facility #1
Naples, Florida
Facility #1
Ocala, Florida
Facility #1
Orlando, Florida
Facility #1
Palm Beach Gardens, Florida
Facility #1
St. Petersburg, Florida
Facility #1
Sunrise, Florida
Facility #3
Tampa, Florida
Facility #1
Tampa, Florida
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.